Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 4/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.30 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935791 | 0.96 | SLC22A1 (0.38) | DNM1SLC22A1SLC22A2ALDH1A1TSHR | |
| Tetrabuthylammonium SCHEMBL9935686 | 0.93 | SLC22A1 (0.46) | DNM1SLC22A1SLC22A2ALDH1A1TSHR | |
| Tetrylammonium SCHEMBL9517155 | 0.85 | TSHR (0.36) | TSHR | |
| Tributylmethylammonium SCHEMBL9936102 | 0.84 | ENPP2 (0.33) | DNM1SLC22A1ALDH1A1TSHRZDHHC20 | |
| SCHEMBL9934679 | 0.82 | DNM1 (0.42) | DNM1SLC22A1SLC22A2ALDH1A1TSHR | |
| Pentadecane SCHEMBL27822400 | 0.81 | TSHR (0.46) | ALDH1A1TSHRTP53ZDHHC20ZDHHC2 | |
| SCHEMBL9935787 | 0.79 | SLC22A1 (0.38) | DNM1SLC22A1SLC22A2ALDH1A1TSHR | |
| SCHEMBL9934338 | 0.77 | DNM1 (0.52) | DNM1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL9935057 | 0.77 | DNM1 (0.52) | DNM1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL16621462 | 0.77 | EPHX2 (0.40) | ALDH1A1TSHRTP53SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546609-B2 | Ionic liquid containing allylsulfonate anion | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| EP-2474527-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | Wako Pure Chemical Industries, Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157680-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157680-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | ATXN2L, ARL1, INPPL1 | DNM1 3583/4885SLC22A1 1635/4885SLC22A2 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.